Please assess the completion status of the following clinical trial:

Trial Title: PPAR-gamma: a Novel Therapeutic Target for Asthma?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 of either sex with a clinical diagnosis of asthma,~* FEV1 ≥ 60% predicted and an increase in FEV1 of greater than 12% following inhaled salbutamol 400μg or Peak Expiratory Flow (PEF) variability \>12% during run-in.~* Allowed medication: 0-800μg inhaled beclomethasone diproprionate or equivalent and as required short acting beta agonist.~Exclusion Criteria:~* Current smoking,~* \> 10 pack years smoking history,~* Treatment with leukotriene antagonists,~* Liver or cardiovascular disease,~* Oral steroid treatment or exacerbation within 6 weeks,~* Females who are pregnant, lactating or not using adequate contraception,~* Any contra-indication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepatic impairment, diabetic ketoacidosis),~* Oral or insulin treatment for diabetes,~* Treatment with gemfibrozil or rifampicin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IMP Pioglitazone (Type: EXPERIMENTAL): Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).